Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Aktis Oncology, Inc. before investing.

In this article, we go over a few key elements for understanding Aktis Oncology, Inc.’s stock price such as:

• Aktis Oncology, Inc.’s current stock price and volume
• Why Aktis Oncology, Inc.’s stock price changed recently
• Upgrades and downgrades for AKTS from analysts
• AKTS’s stock price momentum as measured by its relative strength

About Aktis Oncology, Inc. (AKTS)

Before we jump into Aktis Oncology, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Want to learn more about Aktis Oncology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Aktis Oncology, Inc..

Aktis Oncology, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Aktis Oncology, Inc.’s stock price was $22.070.

Aktis Oncology, Inc. is down 4.04% from its previous closing price of $23.000.

During the last market session, Aktis Oncology, Inc.’s stock traded between $21.340 and $23.140. Currently, there are approximately 48.63 million shares outstanding for Aktis Oncology, Inc..

Aktis Oncology, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Aktis Oncology, Inc. Stock Price History

Aktis Oncology, Inc.’s (AKTS) price is currently down 31.52% so far this month.

During the month of July, Aktis Oncology, Inc.’s stock price has reached a high of $32.380 and a low of $21.340.

Over the last year, Aktis Oncology, Inc. has hit prices as high as $34.190 and as low as $14.720. Year to date, Aktis Oncology, Inc.’s stock is up 59227.96%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Aktis Oncology, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were analysts who downgraded Aktis Oncology, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Aktis Oncology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Aktis Oncology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Aktis Oncology, Inc. (AKTS) by visiting AAII Stock Evaluator.

Relative Price Strength of Aktis Oncology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Aktis Oncology, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Aktis Oncology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Aktis Oncology, Inc. Stock Price: Bottom Line

As of July 31, 2026, Aktis Oncology, Inc.’s stock price is $22.070, which is down 4.04% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Aktis Oncology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.